Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced positive topline data for its Phase 2 SAVITRI™ study. This randomized, double-blind, placebo-controlled dose-finding study assessed the ...

"My depression started to take more of a toll on me," she says. "I had feelings of worthlessness, lost a lot of weight, and I ...

Intra-Cellular Therapies (ITCI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Repetitive transcranial magnetic stimulation has been approved for more than a decade in the US, but Europe still needs clear guidelines.

Expert opinion from Sandeep Kumar Reddy Mallela MBBS BMB Pediatrics persevering · 2 years of experience · India Depression is ...

The study is the first and largest to use an entire country's data to confirm genetic transmission of treatment-resistant ...

High placebo responses common in tests of neuropsychiatric drugs makes any clinical trial in major depressive disorder risky. Intra-Cellular Therapies now has data showing its drug met key goals ...

The FDA has approved the first app for treating major depressive disorder, a condition estimated to impact 21% of U.S. adults at some point in their lifetime. The app, Rejoyn, is intended to ...

One low-dose injection of esketamine administered right after childbirth reduces major depressive episodes, according to a ...

Inner Cosmos implants treatment devices in human brains, and its neurostimulation tech can be used to treat depression.

One low-dose injection of esketamine administered right after childbirth helps reduce major depressive episodes in new ...

Researchers suggest considering low-dose esketamine for individuals experiencing depressive symptoms during pregnancy. A ...